The U.S. Court of Appeals for the Federal Circuit remanded a patent infringement dispute involving Guardant Health, TwinStrand Biosciences and the University of Washington back to the Patent Trial and Appeal Board (PTAB). The case centers on duplex consensus sequencing patents and a jury award that assigned royalties and damages to TwinStrand. The remand could open a route to challenge the validity of one of TwinStrand’s patents under a different legal framework, potentially reducing Guardant’s exposure from the original $83.4 million award and associated royalty calculations. The decision leaves open separate proceedings on another patent undergoing reexamination and will be watched for implications on sequencing IP landscapes and commercial licensing risks.